Publication:

Guillian-Barre syndrome after COVID-19 infection: a case report

Guillain-Barre syndrome (GBS) is an auto-immune disorder characterized by ascending motor weakness with hypo-reflexia or areflexia. In GBS molecular mimicry leads to the targeting of peripheral nerves. The treatment of GBS is mainly supportive, however, the definitive management of GBS includes IVIGs (intravenous immunoglobulins) and plasma exchange (plasmapheresis). We reported a case of 42 year old man who presented with weakness of both lower limbs associated with pain and numbness after recovering from COVID-19 infection. Clinical examination, radiological findings and lab results confirmed the diagnosis of GBS. He was admitted in the hospital and treated with intravenous immunoglobulins along with periodic cardiac, respiratory and neurological assessment. The patient showed a substantial response to intravenous immunoglobulins and resulted in a remarkable recovery with no residual motor or sensory deficit.